Insider filing
Traded Dec 1, 2025 · filed 2 days later
Routine share withholding; mechanical by default.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Oct 31, 2025 · Filed Nov 3, 2025
The CEO of Concentrix paid $40K out of pocket for Concentrix shares.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market purchase
Code P — open-market or private purchase
~$40,000
Shares × reported transaction price
$25K–$100K
+0.3%
Purchase shares ÷ estimated pre-transaction holdings, from the filing
First purchase in 0 months
Confirmed open-market purchases by the same insider in the available history
No
Compared with 2 earlier confirmed purchases
No other insider purchases within 30 days
Distinct insiders at the same issuer with confirmed open-market purchases
This purchase equals less than 1% of the CEO's reported total pay for fiscal 2024 ($11.6M)
Purchase value ÷ the CEO's total from the Summary Compensation Table, as tagged in the pay versus performance table of the company's proxy statement (DEF 14A), filed 2026-02-13. The proxy names Chris Caldwell as CEO for that year. A size comparison, not a judgement
36 days after results of Sep 25, 2025, 74 days before results of Jan 13, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $40.31 on Oct 31, 2025, 8% above its 52-week low and 38% below its high, after a 29% drop over the previous 30 trading days
52-week range $37.26 (Nov 19, 2024) to $65.04 (Mar 27, 2025), 11% of the way up, from 250 adjusted closes. 30 trading days earlier: $56.97 on Sep 19, 2025. Describes the past only, not a forecast
RSI 26, 21% under its 200-day average, 19% under its 50-day average, 38% below the 52-week high, 20-day volatility 40% a year, against the S&P 500: −18 points over 1 month, −20 points over 3 months, −41 points over 6 months
From the adjusted closes up to Oct 31, 2025. RSI: Wilder's 14-day relative strength index (0 to 100). Averages: the last 50 and 200 closes. Volatility: standard deviation of the last 20 daily returns, annualised. S&P 500: the stock's move minus SPY's between the same dates (21, 63 and 126 trading days). Describes the past only, not a forecast
None found in footnotes
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | −11.7% | +1.1% | −12.9% |
| 30 days | −5.2% | +1.4% | −6.6% |
| 90 days | +1.7% | +3.0% | −1.3% |
| 180 days | −39.7% | +6.3% | −46.0% |
| 365 days | −20.7% | +13.6% | −34.3% |
Past results only. Not a forecast.
Insider filing
Traded Dec 1, 2025 · filed 2 days later
Routine share withholding; mechanical by default.
Cormac J Twomey (EVP, Global Ops & Delivery) sold ~$18K of Concentrix
Planned saleFund moves
14 tracked managers disclosed the same change for Q3 2025. From a 13F filed Nov 13, 2025 covering holdings at Sep 30, 2025 — a quarter-end snapshot, not a live trade.
Christopher A Caldwell, President and CEO's past purchases, 90 days after disclosure: 7 buys, median −1.6 pts vs S&P 500, beat it 2 of 7 times. Past results, not a forecast.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.